| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Anticancer; NF-κB;matrix metallopeptidase 2 (MMP2)/MMP9; p-AKT.
The primary target of 7-Methoxy-1-tetralone is associated with its antitumor activity. It has been shown to inhibit tumor growth in subcutaneously implanted tumor models with HepG2 cells. As an impurity of Agomelatine, it is related to melatoninergic and serotonergic signaling pathways. The compound does not have a well-defined receptor target but exerts its effects through antitumor mechanisms. |
|---|---|
| ln Vitro |
7-Methoxy-1-tetralone (31.25-1000 μM; 48 h) suppresses LO2 and HepG2 cell growth [1]. HepG2 cells exposed to 40 μM, 100 μM, or 250 μM of 7-Methoxy-1-tetralone for 48 hours experience apoptosis, and the expression levels of c-Met, p-AKT, AKT, NF-κB, MMP2, and MMP9 proteins are regulated in the cells. [1].
In vitro, 7-Methoxy-1-tetralone demonstrates antitumor activity. It has been shown to inhibit tumor growth in cell-based assays. The compound is used as a key intermediate in organic synthesis. However, detailed in vitro activity data, including IC50 values, are not consistently reported in the available literature. The compound is primarily studied for its antitumor properties and as a synthetic intermediate. |
| ln Vivo |
In HepG2 cell subcutaneously implanted tumor models, 7-Methoxy-1-tetralone (80, 120, or 160 mg/kg/d; intraperitoneal injection; 19 doses total) suppresses tumor growth [1].
In vivo, 7-Methoxy-1-tetralone (80, 120, or 160 mg/kg/d; ip; 19 doses in total) inhibits tumor growth in subcutaneously implanted tumor models with HepG2 cells. The compound demonstrates dose-dependent antitumor activity in vivo. However, detailed pharmacokinetic and pharmacodynamic data are limited in the available literature. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for 7-Methoxy-1-tetralone are not typically performed, as it is primarily studied for its antitumor activity and used as a synthetic intermediate. Quality control assays involve HPLC to verify purity and identity. The compound is also tested for solubility and stability under standard storage conditions. It is soluble in chloroform, ethyl acetate, and methanol.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HepG2 cells Tested Concentrations: 40 μM, 100 μM, and 250 μM Incubation Duration: 48 h Experimental Results: diminished the protein expression levels of c-Met, p-AKT, NF-κB, MMP2, and MMP9. Cell Proliferation Assay[1] Cell Types: LO2 and HepG2 cells Tested Concentrations: 31.25 μM, 62.5 μM, 125 μM, 250 μM, 500 μM, and 1000 μM Incubation Duration: 24 h, 48 h, and 72 h Experimental Results: demonstrated anti-proliferative activity of MT on LO2 and HepG2 cells. In vitro cellular assays for 7-Methoxy-1-tetralone involve testing its antitumor activity against cancer cell lines. Cells (e.g., HepG2) are treated with serial dilutions of the compound (10-200 µM) for 48-72 hours. Cell viability is assessed using MTT or CCK-8 assays. The compound demonstrates concentration-dependent antitumor activity. However, detailed protocols are not well established in the available literature. |
| Animal Protocol |
Animal/Disease Models: BALB/c nude mice (5weeks old) with subcutaneously (sc) implanted HepG2 cells[1]
Doses: 80, 120, or 160 mg/ kg/d Route of Administration: intraperitoneal (ip)injection; sacrificed after 19 days Experimental Results: Resulted the tumor inhibition rates of 40.57% (80 mg/kg), 51.43% (120 mg/kg), 79.43% (160 mg/kg), respectively. In vivo animal studies for 7-Methoxy-1-tetralone involve efficacy testing in tumor-bearing models. Mice implanted with HepG2 cells are treated with 7-Methoxy-1-tetralone (80, 120, or 160 mg/kg/d; ip; 19 doses in total). Tumor volume and body weight are monitored over the treatment period. The compound demonstrates dose-dependent inhibition of tumor growth in vivo. |
| ADME/Pharmacokinetics |
7-Methoxy-1-tetralone has a molecular formula of C11H12O2 and a molecular weight of 176.21. It appears as an off-white powder with a melting point of 59-63°C. It has a density of 1.124±0.06 g/cm3 and a LogP of 2.68. The compound is slightly soluble in water (309 mg/L at 25°C). It is stable under recommended storage conditions at room temperature, sealed in a dry place. It is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 7-Methoxy-1-tetralone includes hazard codes Xn (Harmful) with risk statements R20/21/22 (Harmful by inhalation, in contact with skin and if swallowed) and R36/37/38 (Irritating to eyes, respiratory system and skin). Safety statements include S22 (Do not breathe dust) and S24/25 (Avoid contact with skin and eyes). The compound is intended for research use only and is not approved for clinical use.
|
| References |
[1]. Wen Y, et al. 7-Methoxy-1-Tetralone Induces Apoptosis, Suppresses Cell Proliferation and Migration in Hepatocellular Carcinoma via Regulating c-Met, p-AKT, NF-κB, MMP2, and MMP9 Expression. Front Oncol. 2020 Feb 7;10:58.
|
| Additional Infomation |
7-Methoxy-3,4-dihydro-1(2H)-naphthone belongs to the tetrahydronaphthyl group of compounds. This study aimed to investigate the antiproliferative and antimigration effects of 7-methoxy-1-tetrahydronaphthone (MT) on hepatocellular carcinoma (HCC) cells. HCC cell viability was detected using the MTT assay; HCC cell apoptosis was detected by flow cytometry; HCC cell migration ability was assessed using a scratch assay; protein expression levels were detected by Western blot; the in vivo antitumor effect of MT was tested in a BALB/c nude mouse model, and pathological changes in tumor tissues were assessed by immunohistochemistry. Results showed that MT treatment significantly inhibited the proliferation and migration of HepG2 cells and induced HepG2 cell apoptosis. Western blot experiments showed that MT treatment inhibited the protein expression levels of c-Met, phosphorylated AKT (p-AKT), NF-κB, and matrix metalloproteinase 2 (MMP2)/MMP9 in HepG2 cells. Further in vivo animal experiments showed that MT treatment inhibited tumor growth of HepG2 cells in nude mice, but had no effect on body weight or liver and spleen organ indices. Immunohistochemical analysis of the dissected tumor tissues showed that MT treatment significantly inhibited the protein expression levels of NF-κB, MMP9, MMP2 and p-AKT. In summary, this study confirmed the anti-tumor effect of MT on hepatocellular carcinoma (HCC). MT may inhibit the progression of HCC by regulating mediators related to proliferation and migration in HepG2 cells, including c-Met, p-AKT, NF-κB, MMP2 and MMP9. [1]
7-Methoxy-1-tetralone (CAS 6836-19-7) is a potent antitumor agent and an impurity of Agomelatine, a melatoninergic agonist and selective antagonist of 5-HT2C receptors. It has a molecular formula of C11H12O2 and a molecular weight of 176.21. The compound inhibits tumor growth in subcutaneously implanted tumor models with HepG2 cells at doses of 80-160 mg/kg/d. It is intended for research use only and is not approved for clinical use. |
| Molecular Formula |
C11H12O2
|
|---|---|
| Molecular Weight |
176.2118
|
| Exact Mass |
176.083
|
| CAS # |
6836-19-7
|
| PubChem CID |
81276
|
| Appearance |
Off-white to yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
312.3±31.0 °C at 760 mmHg
|
| Melting Point |
59-63 °C(lit.)
|
| Flash Point |
145.8±18.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.549
|
| LogP |
2.79
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
200
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2C([H])=C(C([H])=C([H])C=2C([H])([H])C([H])([H])C1([H])[H])OC([H])([H])[H]
|
| InChi Key |
GABLTKRIYDNDIN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H12O2/c1-13-9-6-5-8-3-2-4-11(12)10(8)7-9/h5-7H,2-4H2,1H3
|
| Chemical Name |
7-methoxy-3,4-dihydro-2H-naphthalen-1-one
|
| Synonyms |
7-Methoxy-1-tetralone; 6836-19-7; 7-METHOXY-3,4-DIHYDRONAPHTHALEN-1(2H)-ONE; 7-methoxy-3,4-dihydro-2H-naphthalen-1-one; 7-Methoxy-1,2,3,4-tetrahydronaphthalen-1-one; 1(2H)-Naphthalenone, 3,4-dihydro-7-methoxy-; MFCD00001696; H4FZ2W25VZ;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (567.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6750 mL | 28.3752 mL | 56.7505 mL | |
| 5 mM | 1.1350 mL | 5.6750 mL | 11.3501 mL | |
| 10 mM | 0.5675 mL | 2.8375 mL | 5.6750 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
